No Data
No Data
No Data
No Data
No Data
Express News | Minerva Neurosciences Inc - on April 10, Got Notice From Nasdaq That Company Was Not in Compliance With Nasdaq’s Listing Rule
Moomoo 24/7Apr 12 16:08 ET
Top Midday Decliners
Minerva Neurosciences (NERV) said the US Food and Drug Administration rejected its new drug application for roluperidone, an investigational treatment for negative symptoms of schizophrenia, citing "c
MT NewswiresFeb 27 14:04 ET
Sector Update: Health Care Stocks Decline Tuesday Afternoon
Health care stocks were lower Tuesday afternoon, with the NYSE Health Care Index shedding 0.2% and the Health Care Select Sector SPDR Fund (XLV) down 0.1%. The iShares Biotechnology ETF (IBB) rose 1.1
MT NewswiresFeb 27 13:51 ET
Regulatory Setback For Minerva Neurosciences' Schizophrenia Treatment Candidate, FDA Asks For More Data
Minerva Neurosciences Inc (NASDAQ:NERV) shares are trading lower after the FDA issued a Complete Response Letter (CRL) to the company's marketing application for roluperidone for the treatment of nega
BenzingaFeb 27 12:53 ET
BBAI, CTMX and STRC Among Mid-day Movers
Seeking AlphaFeb 27 12:52 ET
Express News | HC Wainwright & Co. Reiterates Neutral on Minerva Neurosciences, Maintains $11 Price Target
Moomoo 24/7Feb 27 12:35 ET
OptionalOptions : Do you just post all FDA info?
No Data
No Data